A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...
Big pharma bets on KRAS G12D as oncology race intensifies Drugmakers chase tough G12D target with degraders and pan-KRAS ...
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...
About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, ...
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is responsible for activation of RAS signaling pathways involved in aggressive tumor ...
Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "KRAS Mutant Cancer - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive ...
Fast track designation targets a post–immunotherapy and post-platinum KRAS G12C–mutant NSCLC population, enabling closer FDA ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results